Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $333

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $340 to $333.